On 6 December 2012, orphan designation (EU/3/12/1073) was granted by the European Commission to Bayer Pharma AG, Germany, for maytansinoid-conjugated human monoclonal antibody against mesothelin for the treatment of mesothelioma.

The sponsorship was transferred to Bayer AG, Germany, in August 2017.

This medicine is now known as anetumab ravtansine.

Key facts

Active substance
Maytansinoid-conjugated human monoclonal antibody against mesothelin (anetumab ravtansine)
Disease / condition
Treatment of malignant mesothelioma
Date of decision
Orphan decision number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Bayer AG
51368 Leverkusen
Tel. +49 30 300 139 003

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating